Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pharmanest Initiates Phase I Trial with SHACT

Published: Monday, October 15, 2012
Last Updated: Monday, October 15, 2012
Bookmark and Share
Trial is expected to enroll 15 patients and the study will be conducted at the Karolinska University Hospital.

Pharmanest AB has announced that the first patient has been dosed in an open label pharmacokinetic study with its drug candidate SHACT, a product developed for pain relief in connection with intrauterine device (IUD) insertion. Karolinska Development AB owns 55% of Pharmanest.

Pharmanest’s Phase I-study is an open study with the objective of establishing the pharmacokinetic properties of SHACT when applied in the cervix and uterus of women receiving an IUD.

Secondary objectives are to evaluate the safety and tolerability. A randomized, double blind Phase II study with about 200 patients is planned to start later this year.

"Every year, millions of women have IUDs inserted. Many women experience pain in connection with the insertion, and there are only few local pain relief products on the market with documented efficacy. Therefore, in most countries, patients have no choice other than oral painkillers or no pain relief at all. We see a great need for local pain relief products in connection with IUD insertions and also in other gynecological procedures”, says Gunilla Lundmark, CEO of Pharmanest.

SHACT is applied topically in the cervix and uterus using applicator developed by Pharmanest. The aim is to achieve immediate pain relief without the use of advanced equipment.

The trial is expected to enroll 15 patients and the study will be conducted at the Karolinska University Hospital, Solna, Sweden. Principal investigator is Dr. Sara Törnblom Paulander, specialist in obstetrics and gynecology.

"As the majority owner of Pharmanest, we are very pleased about the initiation of this trial which marks an important step from preclinical to clinical stage. I am excited about SHACT because it is a product that addresses a clear medical need among millions of women around the world”, says Torbjörn Bjerke, CEO of Karolinska Development AB.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dilafor Enters into a License and Partnership Agreement with Lee’s Pharmaceutical
Dilafor grants the right to manufacture, develop and commercialize tafoxiparin to Lee's Pharmaceutical.
Friday, February 21, 2014
Pergamum Announces Final Data from Phase I/II Study of LL-37
Phase I/II trial of LL-37 for treatment of patients with chronic leg ulcers.
Thursday, October 10, 2013
Lipidor Reports Positive Clinical Phase I/II Data in Psoriasis
Company is developing AKVANO®/calcipotriol for the treatment of psoriasis vulgaris.
Thursday, August 29, 2013
Pharmanest Meets All Efficacy and Safety End Points in Phase II Study of SHACT
Data show that SHACT is effective in reducing pain during IUD insertion.
Monday, August 05, 2013
Pergamum Reports Positive Data from Phase II Clinical Trial of PXL-01
Follow-up data from the Phase II clinical trial for prevention of post-surgical adhesions.
Thursday, June 27, 2013
First Patient Dosed in the Phase I/II Study of UC1010 for PMDD Patients
First patient has been dosed with UC1010 in a double-blind, multicenter study.
Monday, May 27, 2013
Pergamum Reports Top Line Phase II-data from the Clinical Trial of PXL-01
The final Phase II report is expected to be published in the third quarter 2012.
Monday, August 06, 2012
Pharmanest Initiates Phase II Study of SHACT
Goal of the study is to evaluate the effect of SHACT in connection with IUD insertion in women.
Tuesday, June 19, 2012
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!